David H. Collier

11.5k total citations · 1 hit paper
83 papers, 2.8k citations indexed

About

David H. Collier is a scholar working on Rheumatology, Immunology and Hematology. According to data from OpenAlex, David H. Collier has authored 83 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Rheumatology, 31 papers in Immunology and 23 papers in Hematology. Recurrent topics in David H. Collier's work include Rheumatoid Arthritis Research and Therapies (56 papers), Spondyloarthritis Studies and Treatments (22 papers) and Autoimmune and Inflammatory Disorders Research (22 papers). David H. Collier is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (56 papers), Spondyloarthritis Studies and Treatments (22 papers) and Autoimmune and Inflammatory Disorders Research (22 papers). David H. Collier collaborates with scholars based in United States, Canada and United Kingdom. David H. Collier's co-authors include Maureen D. Mayes, Richard W. Martin, Arthur Weinstein, Barbara White, Philip J. Clements, Michael Weisman, Saul J. Weiner, Peter A. Lachenbruch, Fredrick M. Wigley and James R. Seibold and has published in prestigious journals such as Annals of Internal Medicine, CHEST Journal and The American Journal of Medicine.

In The Last Decade

David H. Collier

80 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis.

1995 711 citations Philip J. Clements, Barbara White et al. profile →

Peers

Countries citing papers authored by David H. Collier

Since Specialization

Citations

This map shows the geographic impact of David H. Collier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David H. Collier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David H. Collier more than expected).

Fields of papers citing papers by David H. Collier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David H. Collier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David H. Collier. The network helps show where David H. Collier may publish in the future.

Co-authorship network of co-authors of David H. Collier

This figure shows the co-authorship network connecting the top 25 collaborators of David H. Collier. A scholar is included among the top collaborators of David H. Collier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David H. Collier. David H. Collier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Treatment patterns and clinical outcomes in patients with rheumatoid arthritis initiating etanercept, adalimumab, or Janus kinase inhibitor as first-line therapy: results from the real-world CorEvitas RA Registry 2023 ·Arthritis Research & Therapy ·Dimitrios A. Pappas, Jacqueline O’Brien, Lin Guo, Ying Shan, Joshua F. Baker, Gregory Kricorian, Scott Stryker, David H. Collier	7
2	Real‐World Evidence Assessing Psoriatic Arthritis by Disease Domain: An Evaluation of the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry 2023 ·ACR Open Rheumatology ·Philip J. Mease, Jacqueline O’Brien, (unknown), Gregory Kricorian, Scott Stryker, David H. Collier, Alexis Ogdie	3
3	Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial 2022 ·RMD Open ·Philip Helliwell, Phillip J. Mease, Arthur Kavanaugh, Laura C. Coates, Alexis Ogdie, Atul Deodhar, Vibeke Strand, Gregory Kricorian, (unknown), David H. Collier, Dafna D. Gladman	4
4	The Economic Benefit of Remission for Patients with Rheumatoid Arthritis 2022 ·Rheumatology and Therapy ·Jeffrey R. Curtis, Kathleen M. Fox, Fenglong Xie, Yujie Su, David H. Collier, (unknown), (unknown)	9
5	Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis 2021 ·Rheumatology and Therapy ·Elizabeth Holdsworth, (unknown), Kathleen M. Fox, Pooja Desai, David H. Collier, Daniel E. Fürst	21
6	Treatment patterns in rheumatoid arthritis patients newly initiated on biologic and conventional synthetic disease-modifying antirheumatic drug therapy and enrolled in a North American clinical registry 2021 ·Arthritis Research & Therapy ·Philip J. Mease, Scott Stryker, Mei Liu, Bob Salim, Sabrina Rebello, (unknown), David H. Collier	11
7	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis 2020 ·Lara D. Veeken ·Laura C. Coates, Joseph F. Merola, Philip J. Mease, Alexis Ogdie, Dafna D. Gladman, Vibeke Strand, Leonieke van Mens, (unknown), Priscilla K. Yen, David H. Collier, Gregory Kricorian, James Chung, Philip Helliwell	11
8	Persistence of tumor necrosis factor inhibitor or conventional synthetic disease-modifying antirheumatic drug monotherapy or combination therapy in psoriatic arthritis in a real-world setting 2019 ·Rheumatology International ·Philip J. Mease, Neil A. Accortt, Sabrina Rebello, Carol J. Etzel, Ryan W. Harrison, Girish Aras, (unknown), Jeffrey D. Greenberg, David H. Collier	8
9	The longitudinal effect of biologic use on patient outcomes (disease activity, function, and disease severity) within a rheumatoid arthritis registry 2019 ·Clinical Rheumatology ·Nancy A. Shadick, Nicole Gerlanc, Michelle Frits, Bradley S. Stolshek, (unknown), Christine Iannaccone, David H. Collier, Jing Cui, Alex Mutebi, Michael E. Weinblatt	5
10	Changes in Treatment Patterns in Patients with Psoriatic Arthritis Initiating Biologic and Nonbiologic Therapy in a Clinical Registry 2017 ·The Journal of Rheumatology ·Philip J. Mease, (unknown), Mei Liu, David H. Collier, Marc A. Mason, (unknown), Neil A. Accortt	12
11	Clinical and demographic factors associated with change and maintenance of disease severity in a large registry of patients with rheumatoid arthritis 2017 ·Arthritis Research & Therapy ·George Reed, David H. Collier, Andrew Koenig, Katherine C. Saunders, Dimitrios A. Pappas, Heather J. Litman, Joel M. Kremer, Sameer Kotak	7
12	Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy 2015 ·SpringerPlus ·Kathryn Hobbs, Atul Deodhar, Brian Wang, (unknown), (unknown), James Chung, David H. Collier	14
13	Predictors of Clinical Remission under Anti-tumor Necrosis Factor Treatment in Patients with Ankylosing Spondylitis: Pooled Analysis from Large Randomized Clinical Trials 2015 ·The Journal of Rheumatology ·Xenofon Baraliakos, Andrew Koenig, Heather Jones, Annette Szumski, David H. Collier, Eustratios Bananis	35
14	Use of a validated algorithm to estimate the annual cost of effective biologic treatment for rheumatoid arthritis 2014 ·Journal of Medical Economics ·Jeffrey R. Curtis, Vernon F. Schabert, Jason Yeaw, Jonathan R. Korn, Caroleen Quach, David J. Harrison, Huifeng Yun, George J Joseph, David H. Collier	20
15	Persistence and Dose Escalation of Tumor Necrosis Factor Inhibitors in US Veterans with Rheumatoid Arthritis 2014 ·The Journal of Rheumatology ·Grant W. Cannon, Scott L. DuVall, (unknown), Liron Caplan, Jeffrey R. Curtis, Kaleb Michaud, Ted R. Mikuls, Andreas Reimold, David H. Collier, David J. Harrison, George J Joseph, Brian C. Sauer	25
16	Comparison of Physician and Patient Global Assessments Over Time in Patients With Rheumatoid Arthritis 2013 ·JCR Journal of Clinical Rheumatology ·Joseph A. Markenson, Andrew Koenig, Jing Feng, (unknown), Debra Zack, David H. Collier, Arthur L. Weaver	25
17	Health Literacy Predicts the Discrepancy Between Patient and Provider Global Assessments of Rheumatoid Arthritis Activity at a Public Urban Rheumatology Clinic 2010 ·The Journal of Rheumatology ·Joel M. Hirsh, (unknown), David H. Collier, (unknown), Liron Caplan	41
18	A Concise Evaluation and Management Curriculum for Physicians in Training Improved Billing at an Outpatient Academic Rheumatology Clinic 2010 ·JCR Journal of Clinical Rheumatology ·Joel M. Hirsh, David H. Collier, (unknown), Edward M. Gardner	6
19	Recombinant Human Relaxin in the Treatment of Scleroderma 2000 ·Annals of Internal Medicine ·James R. Seibold, Joseph H. Korn, Robert W. Simms, Phillip J. Clements, Larry W. Moreland, Maureen D. Mayes, Daniel E. Fürst, Naomi F. Rothfield, Virginia Steen, Michael Weisman, David H. Collier, Fredrick M. Wigley, Peter A. Merkel, Mary Ellen Csuka, Vivien Hsu, (unknown), Mark Erikson, John H. Hannigan, W. Scott Harkonen, Martin E. Sanders	44
20	High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: Analysis of a two-year, double-blind, randomized, controlled clinical trial 1999 ·Arthritis & Rheumatism ·Philip J. Clements, Daniel E. Fürst, Weng Kee Wong, Maureen D. Mayes, Barbara White, Fredrick M. Wigley, Michael H. Weisman, Walter G. Barr, Larry W. Moreland, Thomas A. Medsger, Virginia Steen, Richard W. Martin, David H. Collier, Arthur Weinstein, Edward V. Lally, John Varga, Steven Weiner, Brian S. Andrews, Micha Abeles, James R. Seibold	210

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact